← SEC 公告列表 | LKFT SEC 公告 | Lakefront Biotherapeutics（LKFT）

重大事件 外國發行人報告 6-K 2026-07-15

Lakefront Biotherapeutics回購108,645股涉資約290萬歐元

於 SEC 網站開啟原文

AI 繁中摘要

申報類型：6-K（外國發行人報告） 事件重點：Lakefront Biotherapeutics（前稱Galapagos）於2026年7月14日公佈，根據2026年6月9日宣布的股份回購計劃，在2026年7月6日至10日期間，通過Euronext Amsterdam及多個交易場所（CEUX、TQEX、AQEU）合共回購108,645股普通股，平均每股作價26.67歐元，總回購金額約290萬歐元（2,897,722.65歐元），回購價格範圍介乎每股26.14歐元至27.00歐元。 截至2026年7月10日收市，公司合共持有412,401股庫存股。Lakefront Biotherapeutics為一家專注免疫與炎症領域的生物科技公司，核心資產為潛在首創BCMAxCD3 T細胞銜接分子gamgertamig，針對自體免疫疾病。 管理層未有在本次公告中就未來業績或展望發表具體指引，但股份回購行動反映公司對自身財務狀況及股東價值的信心。對投資者而言，回購有助於提升每股盈利（EPS）及股東回報，短期或對股價形成支持，惟投資者需注意相關前瞻性陳述涉及風險，詳細風險因素可參閱公司提交予SEC的20-F年報及後續文件。
展開英文正文 
EX-99.1
2
exh_991.htm
PRESS RELEASE

EdgarFiling

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; 14 July 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 108,645 Lakefront shares between 06 July 2026 and 10 July 2026, as follows:

 
 Date
 of purchase
 Market/MTF
 Number
 of shares
 Average
 price paid (€)
 Total
 (€)
 Lowest
 price paid (€)
 Highest
 price paid (€)

 
 06/07/2026
 XAMS
 20,236
 26.54
 536,964.28
 26.20
 26.90

 
 06/07/2026
 CEUX
 2,499
 26.69
 66,710.06
 26.32
 26.90

 
 06/07/2026
 TQEX
 355
 26.72
 9,486.20
 26.52
 26.90

 
 06/07/2026
 AQEU
 319
 26.58
 8,477.65
 26.52
 26.88

 
 07/07/2026
 XAMS
 16,553
 26.65
 441,104.34
 26.40
 26.86

 
 07/07/2026
 CEUX
 1,578
 26.55
 41,894.01
 26.44
 26.76

 
 07/07/2026
 TQEX
 821
 26.64
 21,872.92
 26.60
 26.70

 
 07/07/2026
 AQEU
 49
 26.60
 1,303.40
 26.60
 26.60

 
 08/07/2026
 XAMS
 17,502
 26.84
 469,793.93
 26.66
 27.00

 
 08/07/2026
 CEUX
 4,339
 26.89
 116,674.84
 26.74
 26.96

 
 08/07/2026
 TQEX
 1,157
 26.87
 31,086.62
 26.76
 26.94

 
 08/07/2026
 AQEU
 416
 26.86
 11,172.18
 26.80
 26.94

 
 09/07/2026
 XAMS
 16,919
 26.77
 452,892.87
 26.56
 26.90

 
 09/07/2026
 CEUX
 2,717
 26.79
 72,781.09
 26.70
 26.96

 
 09/07/2026
 TQEX
 23
 26.76
 615.48
 26.76
 26.76

 
 09/07/2026
 AQEU
 400
 26.77
 10,707.04
 26.76
 26.78

 
 10/07/2026
 XAMS
 19,764
 26.52
 524,208.48
 26.14
 26.90

 
 10/07/2026
 CEUX
 2,009
 26.66
 53,568.98
 26.26
 26.92

 
 10/07/2026
 TQEX
 692
 26.65
 18,443.74
 26.24
 26.78

 
 10/07/2026
 AQEU
 297
 26.82
 7,964.53
 26.26
 26.92

 
 Total
  
 108,645
 26.67
 2,897,722.65
 26.14
 27.00

 

As of market close on 10 July 2026, Lakefront holds 412,401 of its own ordinary shares.

About Lakefront BiotherapeuticsLakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology
company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The
Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class
BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong
capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient
impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:Investor Relations Sherri Spear+1
412 522 [email protected]

Forward-looking statementsThis press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often,
but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.